Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 17;16(8):1243–1254. doi: 10.1093/ecco-jcc/jjac036

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 2. — Pharmacokinetic parameters of VDZ AUC, C_avg and C_trough at Week 14 in patients with [A] ulcerative colitis and [B] Crohn’s disease [pharmacokinetic analysis set]. N = 88; one patient was randomized but not treated. The pharmacokinetic analysis set was defined as all patients who received at least one dose of VDZ and had at least one measurable concentration of VDZ. AUC, area under the serum concentration curve; C_avg, average concentration; C_trough, observed serum concentration at the end of the dosing interval; CV, coefficient of variation; IQR, interquartile range; SD, standard deviation; VDZ, vedolizumab; WK, Week.